Anavex Life Sciences Corp (AVXL)

[nidan7500]

Question this scenario? Post, then, a single statement by any competent neurology researcher telling why the Anavex story, the Anavex mechanisms of action are bogus. The silence on this, from the many thousands of neurology researchers across the globe is probably the most affirmative “statement” about the viability of the Anavex story.

Researchers know. But that knowledge, to be useful, requires a pretty elevated level of cytology, nerve physiology, biochemistry, and the many other topics of expertise required for neuron research. Few (Any?) on the street, or here at home, on the investment website screens, can see the Anavex story as being anything more than an over-hyped story simply too good to be true.

That will continue to be the case until something appears that non-science, lay investors can understand: incontrovertibly positive human clinical trial outcomes.

I predict those will first appear in little girls suffering from Rett Syndrome. For all, may it be soon.

Thanks again Falconer for your added value here. We (me) are seeing more clearly each day that the processes previously used by regulatory (BP/FDA) w/massively expensive trial costs will soon be a thing of the past. The old days when massive trials were done (B/C true knowledge of disease causes did not exist). I completely agree that RETT trials w/a smaller population, well directed/controlled, will produce BTD results. The RWE will get out quickly and a new ballgame will be opened.

A critical difference in the A2-73 Rett trials, as you have pointed out, is of course that we truly expect A2-73 to address the root cause. This obviates the need for large statistical rationale. It is a game changer.

There has been NO CONTRADICTORY EVIDENCE presented on Dr.M. claims to date.